Yueqiang Wen

Dr. Yueqiang Wen


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2025 in Phytomedicine
Verified
Journal Article
Closed access
ZWZexin Wang
Zexin Wang
YLYubing Li
Yubing Li
XWXiaobao Wang
Xiaobao Wang
WZWenwen Zhang
Wenwen Zhang
YCYuan Chen
Yuan Chen
Thomas EfferthThomas Efferth
Thomas Efferth

31 October 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
WLWenhao Liao
Wenhao Liao
YWYueqiang Wen
Yueqiang Wen
JWJing Wang
Jing Wang
MZMaoyuan Zhao
Maoyuan Zhao
SLShangbin Lv
Shangbin Lv
JZJinhao Zeng
Jinhao Zeng

30 November 2024 in Pharmacological Research
Verified
Journal Article
Open access
XLXinyue Liu
Xinyue Liu
YCYilin Cai
Yilin Cai
YZYuanhao Zhang
Yuanhao Zhang
HZHetian Zhang
Hetian Zhang
STSisi Tian
Sisi Tian
JZJinhao Zeng
Jinhao Zeng
Liver cancer represents a multifactorial, multistage, and intricately progressive malignancy. Over the past decade, artesunate (ART), initially renowned for its anti-malarial efficacy, has been the focus of over 3000 studies uncovering its diverse pharmacological actions, including anti-inflammatory, immunoregulatory, metabolic regulatory, anti-fibrotic, and anti-cancer properties. This review highlights ART's role in the multistep progression from hepatitis to cancer and its underlying regulatory mechanisms, revealing signal transducer and activator of transcription 3 (STAT3) and ferroptosis (a novel form of programmed cell death) as promising therapeutic targets. ART demonstrates efficacy in inhibiting hepatitis virus infections, modulating inflammation, and facilitating recovery from inflammatory processes. During stages of hepatic fibrosis or cirrhosis, ART reverses fibrotic and cirrhotic changes by suppressing hepatic stellate cell activity, regulating inflammatory pathways, inhibiting hematopoietic stem cell proliferation, and inducing ferroptosis. Additionally, ART hinders hepatocellular carcinoma (HCC) cell proliferation, invasion, and metastasis, induces apoptosis and autophagy, combats drug resistance, and enhances chemosensitivity. Collectively, ART exhibits multi-step actions across multiple targets and signaling pathways, highlighting its potential as a clinical candidate for the prevention and treatment of liver cancer, from hepatitis and hepatic fibrosis to advanced HCC.

18 December 2022 in Phytomedicine
Verified
Journal Article
Closed access
MZMaoyuan Zhao
Maoyuan Zhao
YYYi Yang
Yi Yang
QNQing Nian
Qing Nian
CSCaifei Shen
Caifei Shen
XXXiaolin Xiao
Xiaolin Xiao
JZJinhao Zeng
Jinhao Zeng

7 September 2023 in Molecules
Verified
Journal Article
Open access
PDF file
QHQichao Hu
Qichao Hu
SHShuyu Hou
Shuyu Hou
BXBaoyi Xiong
Baoyi Xiong
YWYueqiang Wen
Yueqiang Wen
JWJundong Wang
Jundong Wang
FWFang Wang
Fang Wang
The gut–brain axis is an active area of research. Several representative diseases, including central nervous system disorders (Alzheimer’s disease, Parkinson’s disease, and depression), metabolic disorders (obesity-related diseases), and intestinal disorders (inflammatory bowel disease and dysbiosis), are associated with the dysfunctional gut–brain axis. Baicalin, a bioactive flavonoid extracted from Scutellaria baicalensis, is reported to exert various pharmacological effects. This narrative review summarizes the molecular mechanisms and potential targets of baicalin in disorders of the gut–brain axis. Baicalin protects the central nervous system through anti-neuroinflammatory and anti-neuronal apoptotic effects, suppresses obesity through anti-inflammatory and antioxidant effects, and alleviates intestinal disorders through regulatory effects on intestinal microorganisms and short-chain fatty acid production. The bioactivities of baicalin are mediated through the gut–brain axis. This review comprehensively summarizes the regulatory role of baicalin in gut–brain axis disorders, laying a foundation for future research, although further confirmatory basic research is required.

15 July 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
JZJun Zhou
Jun Zhou
JLJiqiang Li
Jiqiang Li
JCJie Chen
Jie Chen
XLXi Lan
Xi Lan
YAYanling Ai
Yanling Ai
JZJinhao Zeng
Jinhao Zeng